Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 601–700 of 902
Zane, L. K., Sibon, D., Capraro, V., Galia, P., Karam, M., Delfau‐Larue, M., Gilson, É., Gessain, A., Gout, O., Hermine, O., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26270 · Cited by 18
Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence
Brookes, S., Gagrica, S., Sanij, E., Rowe, J., Gregory, F. J., Hara, E., & Peters, G. G. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1010866 · Cited by 21
Self-citationp16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma.
Lee, A. W. C., Li, J., Shi, W., Li, A., Ng, E., Liu, T.-J., Klamut, H. J., & Liu, F. (2003) · PubMed · Cited by 18
Qiu, M., Liang, Z., Chen, L., Tan, G., Liu, L., Wang, K., Chen, H., & Liu, J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4147 · Cited by 20
“Furthermore, Bmi-1 is reported as an oncogene, which acts by regulating the expression of cell cycle inhibitors p14 and p16 (11,12,36,37).”
Cell-Cycle Control in Embryonic Stem Cells
Savatier, P., & Malashicheva, A. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50014-6 · Cited by 22
An immunohistochemical study of p16INK4a expression in multistep thyroid tumourigenesis
Ball, E., BOND, J. A., Franc, B., DeMicco, C., & Wynford‐Thomas, D. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.025 · Cited by 18
Goumenou, A. G., Matalliotakis, I., Tzardi, M. N., Fragouli, I., MAHUTTE, N. G., & Arici, A. M. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.11.032 · Cited by 18
Molecular Biology of Malignant Mesothelioma: A Review
Pisick, E. P., & Salgia, R. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.09.012 · Cited by 19
“The initial phosphorylation of pRb is caused by the cyclin D-CDK and CDK6 complexes and depends on mitogen [50,58–60,66–71].”
BackgroundMolecular Pathogenesis of Transplacentally Induced Mouse Lung Tumors
Miller, M. S., Leone‐Kabler, S., Rollins, L. A., Wessner, L. L., Fan, M., Schaeffer, D. O., McEntee, M. F., & O’Sullivan, M. G. (1998) · Experimental Lung Research · doi:10.3109/01902149809087386 · Cited by 18
Roth, J. A., & Grammer, S. F. (2003) · Humana Press eBooks · doi:10.1385/1-59259-329-1:577 · Cited by 19
Regulation of the Cell Cycle by the Rb Tumor Suppressor Family
Ewen, M. E. (1998) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69686-5_7 · Cited by 22
Hengstschläger, M., Pusch, O., Hengstschläger-Ottnad, E., Ambros, P. F., BERNASCHEK, G., & Wawra, E. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.41 · Cited by 18
“Texas Red-positive cells were counted under microscope (details of the method are described in Schulze et al, 1994; Lukas et al, 1995).”
Itoh, N., Kakehi, Y., Akao, T., Kinoshita, H., Okada, Y., & Yoshida, O. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00371.x · Cited by 18
Clinical Significance of P16 Gene Methylation in Lung Cancer
Li, Y., Zhang, T., Zhang, H., Wang, X., Liu, X., Huang, Q., & Li, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4494-1_11 · Cited by 18
Acharya, S., Chatterjee, S., Kumar, P., Bhattacharjee, M., Chaudhuri, S., & Chaudhuri, S. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833276e8 · Cited by 18
Loignon, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.35 · Cited by 17
Loss of p15/Ink4b accompanies tumorigenesis triggered by complex DNA double-strand breaks
Camacho, C. V., Mukherjee, B., Mcellin, B. M., Ding, L.-H., Hu, B., Habib, A. A., Xie, X., Nirodi, C. S., Saha, D., Story, M. D., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq153 · Cited by 19
Hama, S., Matsuura, S., Tauchi, H., Yamasaki, F., Kajiwara, Y., Arita, K., Yoshioka, H., Heike, Y., Mandai, K., & Kurisu, K. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601299 · Cited by 17
“Similarly, p16 inhibits the ability of CDK4 and CDK6 to regulate the phosphorylation status of pRb, thereby also controlling progression into the S phase (Nobori et al, 1994; Lukas et al, 1995).”
BackgroundTham, T., Teegala, S., Bardash, Y., Herman, S. W., & Costantino, P. (2018) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2018.07.005 · Cited by 17
RB1 and CDKN2A Functional Defects Resulting in Retinoblastoma
Бабенко, О. В., Zemlyakova, V. V., Saakyan, S. V., Af, B., Strelnikov, V. V., Zaletaev, D. V., & Nemtsova, M. V. (2002) · Molecular Biology · doi:10.1023/a:1020607010296 · Cited by 17
Higashi, H., Suzuki‐Takahashi, I., Yoshida, E., Nishimura, S., & Kitagawa, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6181 · Cited by 18
Mutation and mutagenesis in inherited and acquired human disease
Evans, H. J. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(95)00201-4 · Cited by 17
Frederiksen, K. S., Petri, A., Abrahamsen, N., & Poulsen, H. S. (1999) · Lung Cancer · doi:10.1016/s0169-5002(99)00012-4 · Cited by 19
Thullberg, M., Welcker, M., Bártková, J., Kjerulff, A. A., Lukas, J., Johan, H. V. E., & Bartek, J. (2000) · Hybridoma · doi:10.1089/027245700315806 · Cited by 17
“To produce MAbs against p15, p18, p19, and p21, GS T-tagged or Hi s-tagged proteins containing the full-length human Immunoprecipitation a Antibody Specificity Isotype Western blot a (co-precipitated proteins) Immunofluorescence a Immunohistochemistr y a DCS 110 p15, p16 IgG2a cyclin D, PCNA) a Reactivity: ( 1 1 ) str…”
Self-citationYoung, A. P., & Longmore, G. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207187 · Cited by 20
“…in the accumulation of hypophosphorylated (active) Rb, which leads to growth arrest (Lukas et al., 1995). p16 is capable of inducing senescence in cells in culture (Dai and Enders, 2000), but is unable to induce cell cycle arrest in the absence of Rb (Lukas et al., 1995; Medema et al., 1995).”
BackgroundIsotope-Labeling Strategy for the Assignment of Protein Fragments Generated for Mass Spectrometry
Miranker, A. D., Kruppa, G. H., Robinson, C. V., Aplin, R. T., & Dobson, C. M. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9531236 · Cited by 17
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
Sikic, D., Taubert, H. W., Breyer, J., Eckstein, M., Weyerer, V., Keck, B., Kubon, J., Otto, W., Worst, T. S., KRIEGMAIR, M. C., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s318893 · Cited by 16
Radulescu, R. T., Duckworth, W. C., Levy, J. L., & Fawcett, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.157 · Cited by 16
Chebel, A., Chien, W. W., Gerland, L., Mekki, Y., Bertrand, Y., Ffrench, P., Galmarini, C. M., & Ffrench, M. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.03.021 · Cited by 18
Prognostic impact ofp15gene aberrations in acute leukemia
Braekeleer, M. D., Douet‐Guilbert, N., & Braekeleer, E. D. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1201574 · Cited by 21
“tion from G1 phase to S phase of the cell cycle.[11] p14 binds directly to the p53 negative regulator,”
BackgroundAl‐Khalaf, H. H., Nallar, S. C., Kalvakolanu, D. V., & Aboussekhra, A. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22627 · Cited by 17
Haas, S., Hörmann, K., & Bosch, F. X. (2002) · Oral Oncology · doi:10.1016/s1368-8375(01)00108-7 · Cited by 18
Ikenoue, T., Jingushi, S., Urabe, K., Okazaki, K., & Iwamoto, Y. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19991101)75:2<206::aid-jcb3>3.0.co;2-t · Cited by 64
Grimison, B., Langan, T. A., & Sclafani, R. A. (2000) · PubMed · Cited by 18
Mori, A., Higashi, H., Hoshikawa, Y., Imamura, M., Asaka, M., & Hatakeyama, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203044 · Cited by 17
“Furthermore, whereas growth of certain cells is strongly inhibited by pRB (Tam et al., 1994; Koh et al., 1995; Lukas et al., 1995a,b; Medema et al., 1995), proliferation of hematopoietic cells is e ectively blocked by p130 but not by pRB (Hoshikawa et al., 1998a).”
BackgroundYeudall, W. A., Jakus, J., Ensley, J. F., & Robbins, K. C. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199702)18:2<66::aid-mc2>3.0.co;2-o · Cited by 45
Induction of p16/INK4a Gene Expression and Cellular Senescence by Toyocamycin.
Kurihara, Y., Egawa, K., Kunimoto, S., TAKEUCHI, T., & Nose, K. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1272 · Cited by 16
Rad54L promotes bladder cancer progression by regulating cell cycle and cell senescence
Chen, M., Wang, Y., Zhou, T., Wen, S., Chen, H., Wen, S., & Dao, P. (2022) · Medical Oncology · doi:10.1007/s12032-022-01751-7 · Cited by 18
“Mechanistically, p16 can specifically inhibit the phosphorylation of RB, which finally contributes the cell senescence via cell cycle arrested in G1/S phase[33][34].”
BackgroundMelanoma in Childhood: Review and Perspectives
Spatz, A., & Avril, M. (1998) · Pediatric and Developmental Pathology · doi:10.1007/s100249900064 · Cited by 15
Epigenetic Changes Accompanying Human Mammary Epithelial Cell Immortalization
Yaswen, P., & Stampfer, M. R. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1011364925259 · Cited by 16
“p16 is known to inhibit cell cycle progression by competing with activating D type cyclins for association with cdk4 or cdk6, thereby preventing phosphorylation of Rb (8).”
BackgroundOn the development of biophysical models for space radiation risk assessment
Cucinotta, F. A., & Dicello, J. F. (2000) · Advances in Space Research · doi:10.1016/s0273-1177(99)01065-0 · Cited by 16
Haviernik, P., Schmidt, M., Hu, X., & Wolff, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206268 · Cited by 15
“Therefore, INK4 proteins cannot function in cells lacking pRB (Guan et al., 1994; Lukas et al., 1995; Medema et al., 1995; Ruas and Peters, 1998; Malumbres et al., 2000a).”
BackgroundChristman, S. A., Kong, B. C., Landry, M. M., Kim, H., & Foster, D. N. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-27 · Cited by 19
“The p16INK4a gene is inactivated in many tumor cell lines [2931], while overexpression of p16INK4a results in G1 arrest [32].”
BackgroundInterlandi, G., Settanni, G., & Caflisch, A. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20953 · Cited by 15
Management of malignant melanoma: new developments in immune and gene therapy
Schneeberger, A., Goos, M., Stingl, G., & Wagner, S. N. (2000) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2000.00694.x · Cited by 15
Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity
Kim, C. J., Tambe, Y., Mukaisho, K., Sugihara, H., Kawauchi, A., & Inoue, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.5286 · Cited by 14
Graham, M. K., Principessa, L., Antony, L., Meeker, A. K., & Isaacs, J. T. (2016) · The Prostate · doi:10.1002/pros.23276 · Cited by 15
Tang, Y., Yang, C., Guo, Z., Fu, Y., Yu, X., Liu, B.-G., Zhou, H., Wang, J., Li, W., & Pang, Q. (2017) · Medicine · doi:10.1097/md.0000000000006714 · Cited by 16
Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats
Strauss, B. E., Fontes, R. B. V., Lotfi, C. F. P., Skorupa, A. L., Bartol, I., Cipolla‐Neto, J., & Costanzi-Strauss, E. (2002) · Cancer Cell International · doi:10.1186/1475-2867-2-2 · Cited by 14
Fujiwara, H., Arima, N., Hashimoto-Tamaoki, T., Matsushita, K., Ohtsubo, H., Arimura, K., Hidaka, S., & Tei, C. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00035-1 · Cited by 14
Alevizopoulos, K., Sanchez, B., & Amati, B. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203534 · Cited by 18
“For example, pRb-negative cells become insensitive to expression of p16 or microinjection of antibodies neutralizing cyclin D/CDK4 (Koh et al., 1995; Lukas et al., 1994, 1995a,b; Medema et al., 1995) and ectopic expression of E2F-1 prevents G1 arrest by p16 (Alevizopoulos et al., 1997; DeGregori et…”
BackgroundMiura, K., Ishida, K., Fujibuchi, W., Ito, A., Niikura, H., Ogawa, H., & Sasaki, I. (2012) · Surgery Today · doi:10.1007/s00595-012-0167-z · Cited by 13
DeWire, M. D., Lazow, M., Campagne, O., Leach, J., Fuller, C. E., Kumar, S. S., Stanek, J. R., de Blank, P. M. K., Hummel, T. R., Pillay‐Smiley, N., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac055 · Cited by 18
“…Ribociclib (LEE011; Novartis Pharmaceuticals), an orally bioavailable CDK4/6 inhibitor that induces G1 cell cycle arrest by hypo-phosphorylating RB, 23,24 is FDA-approved for the treat-ment of advanced breast cancer, and has been studied in combination with everolimus and exemestane, 18,20,25 with…”
InfluentialZhang, J., Zhou, J., Ren, X., Diao, Y., Li, H., Jiang, H., Ding, K., & Pei, D. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9577-1 · Cited by 13
Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases
Martin, N. G., McAndrew, P. C., Eve, P. D., & Garrett, M. D. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06463.x · Cited by 16
Ying, C. (2000) · Endocrine Journal · doi:10.1507/endocrj.47.1 · Cited by 13
Okamura, M., Sumida, K., Muto, T., Kashida, Y., Machida, N., Watanabe, T., & Mitsumori, K. (2004) · Archives of Toxicology · doi:10.1007/s00204-004-0589-5 · Cited by 13
“Proteins p16INK4a and p15 are known as CDK inhibitors that induce cell cycle arrest and act as tumor suppressors (Lukas et al. 1995).”
BackgroundFluorescence-activated cell sorting of transfected cells
Adams, P. D., Lopez, P., Sellers, W. R., & Kaelin, W. G. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)83007-8 · Cited by 13
Ookawa, K., Tsuchida, S., Kohno, T., & Yokota, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02583-2 · Cited by 13
Nagore, J. C. E. (2000) · Acta Dermato Venereologica · doi:10.1080/000155500300012936 · Cited by 13
Cancer: Exploring the bowels of DNA methylation
Balmain, A. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00204-1 · Cited by 13
Inactivation of the p15 INK4B and p16 INK4 Genes in Hematologic Malignancies
Heyman, M. M., & Einhorn, S. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609054826 · Cited by 17
MacLellan, W. R., & Schneider, M. D. (1999) · Elsevier eBooks · doi:10.1016/b978-012329860-7/50025-8 · Cited by 13
Zhao, H., Zhang, X., Han, Z., & Wang, Y. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12535 · Cited by 12
Cheng, H., Gao, X., Huard, M., Lu, A., Ruzbarsky, J. J., Amra, S., Wang, B., & Huard, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03047-z · Cited by 15
Lifshagerd, M. R., & Safari, F. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03067-4 · Cited by 13
Cellular and molecular evidence for malignancy-inhibitory functions of p15RS
Zhang, X., Qiu-Ju, C. A. O., Liu, X., LIU, S., Wang, J., Sun, S., Wang, O., Tian, Z., Huitu, L., Kuang, J., et al. (2012) · Cell Cycle · doi:10.4161/cc.20400 · Cited by 13
The Lens: Historical and Comparative Perspectives
Robinson, M. L., & Lovicu, F. J. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.002 · Cited by 14
Elliott, M. J., Stilwell, A., Dong, Y., Yang, H. L., Wong, S. L., Wrightson, W. R., Martin, R. C. G., & McMasters, K. M. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700458 · Cited by 15
“A growing body of evidence points to an opposing relationship between E2F-1 and p21 in both cell cycle control and mediation of apoptosis.(16) - 29 Transciptional targets of E2F-1 include cdk2 and pcna genes favoring cell cycle progression.”
BackgroundBae, S. M., Kim, Y., Lee, J. M., Namkoong, S. E., Kim, C. K., & Ahn, W. S. (2004) · Cancer Research and Treatment · doi:10.4143/crt.2004.36.1.31 · Cited by 12
Grim, J. E., & Clurman, B. E. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00148-x · Cited by 12
The Early Detection of Occult Lung Cancer
Tockman, M. S., & Mulshine, J. L. (2000) · Chest Surgery Clinics of North America · doi:10.1016/s1052-3359(25)00539-3 · Cited by 12
Yang, V. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00015-4 · Cited by 12
González-Vasconcellos, I., Domke, T., Kuosaite, V., Esposito, I., Sanli-Bonazzi, B., Nathrath, M., Atkinson, M. J., & Rosemann, M. (2010) · Radiation and Environmental Biophysics · doi:10.1007/s00411-010-0339-4 · Cited by 14
“Whereas hypophosphorylated Rb1 protein can bind and antagonize S phase promoting transcription factors, thereby keeping cells at G1arrest, the p16 protein is an inhibitor of the Rb1 phosphorylation and hence keeps Rb1 in its active and growth-suppressing state ( Lukas et al. 1995 ).”
BackgroundVanneste, R., Smith, E., & Graham, G. E. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35884 · Cited by 11
“Through alternative splicing of the first exon, CDKN2A encodes two different tumor suppressor proteins, p16INK4A (p16) and p14(ARF) (p14) [Koh et al., 1995; Lukas et al., 1995; Mao et al., 1995; Quelle et al., 1995; Sherr and Roberts, 1995; Stone et al., 1995].”
BackgroundJones, C. (2000) · Breast Cancer Research · doi:10.1186/bcr-2000-66675 · Cited by 11
Ruiz-Miró, M., Colomina, N., Fernández-Hernández, R., Garí, E., Gallego, C., & Aldea, M. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01176.x · Cited by 11
Schwerer, M. J., Sailer, A., Kraft, K., Baczako, K., & Maier, H. (2003) · PubMed · doi:10.14670/hh-18.145 · Cited by 11
Female-specific rectal carcinogenesis in cyclin D1b transgenic mice
Kim, C. J., Tambe, Y., Mukaisho, K., Sugihara, H., Isono, T., Sonoda, H., Shimizu, T., Kondoh, G., & Inoue, H. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt293 · Cited by 11
Loss of p16/CDKN2A Protein in Epstein-Barr Virus-Associated Gastric Carcinoma
Koriyama, C., Kitajima, S., Nomoto, M., Sueyoshi, K., Itoh, T., Eizuru, Y., Yonezawa, S., & Akiba, S. (2004) · Oncology · doi:10.1159/000080290 · Cited by 11
Roca, R., Kypta, R. M., & Vivanco, M. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0634912100 · Cited by 12
The retinoblastoma gene family: its role in cancer onset and progression
Cinti, C., & Giordano, A. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.6.765 · Cited by 11
“Loss of p16 expression, a cyclin-dependent kinase inhibitor, due to deletion or homozygous mutations, has also been found in hereditary melanoma, carcinomas of the pancreas, lung, oesophagus, ovary, kidney and nasopharynx as well as in T-cell acute lymphocytic leukaemia, sarcoma and glioma [167,171,172].”
BackgroundNPC Natural Product Communications
Khana, S. I., Hester, J. P., Tekwania, B. L., Midiwob, J. O., Muhammada, I., Jaina, S. K., Jacoba, M. R., Walkera, L. A., Rahmana, A. A., & Samoylenkoa, V. (2011) · Cited by 11
Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance
Xu, Y., Yang, M., Xu, Y., Han, J., & Zhu, Q. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189356 · Cited by 12
Wu, L., Yu, Y., Zhou, J., Wang, X., Li, J., & Wang, Y. (2020) · Immunotherapy · doi:10.2217/imt-2020-0038 · Cited by 10
The Molecular Genetics of Therapeutic Resistance in Malignant Astrocytomas
Jennings, M. T., & Iyengar, S. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101020-00002 · Cited by 10
NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins
Rothweiler, U., Czarna, A., Weber, L., Popowicz, G. M., Brongel, K., Kowalska, K., Orth, M., Stemmann, O., & Holak, T. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002813 · Cited by 11
Contribution of the dual coding capacity of the p16INK4a/MTS1/CDK2 locus to human malignancies
Larsen, C. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_9 · Cited by 14
The INK4a/ARF Locus and Human Cancer
Enders, G. H. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:197 · Cited by 14
Nylandsted, J., Rohde, M., Bártek, J., & Strauss, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01089-8 · Cited by 10
Self-citationThe D-Type Cyclins: A Historical Perspective
Sherr, C. J., & Siciński, P. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_1 · Cited by 16
Analysis of p16INK4A gene promoter in male germ-cell tumors: identification of a new point mutation
Fombonne, J., Devouassoux‐Shisheboran, M., Bouvier, R., Droz, J., Benahmed, M., & Krantic, S. M. (2004) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2004.08.005 · Cited by 9
Weebadda, W. K. C., Jackson, T. J., & Lin, A. W. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20372 · Cited by 9
“The INK4 family proteins are known to specifically bind to and inhibit cdk4 and cdk6, leading to the inactivation of cyclin D–cdk4/6 complexes, which are required for Rb phosphorylation during G1-S transition [Serrano et al., 1993; Medema et al., 1995; Lukas et al., 1995b; Ruas and Peters, 1998; Sherr, 2000].”
BackgroundInfluentialQureshi, M. A., Jan, N., Dar, N. A., Hussain, M., & Andrabi, K. I. (2012) · Biomarkers · doi:10.3109/1354750x.2012.699556 · Cited by 9
“Homozygous deletions of p16 gene and other loss of function mutations have been reported in a variety of tumors including esophageal squamous cell carcinoma (ESCC; Holland et al. 1994; Cairns et al. 1994; Caldas et al. 1994; Kamb et al. 1994b; Mori et al. 1994; Nobori et al. 1994; Hussussian et al. 1994; Lukas et al.…”
BackgroundCyclin D1 Gene Amplification and p16 Gene Deletion in Patients With Esophageal Carcinosarcoma
Suzuki, H., Fujioka, Y., & Nagashima, K. (1998) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199810000-00004 · Cited by 9
Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment
Jazii, F. R. (2012) · InTech eBooks · doi:10.5772/1196 · Cited by 10
Stage IIIB Non-Small-Cell Lung Cancer
Rendina, E. A., Venuta, F., Giacomo, T. D., & Coloni, G. F. (2001) · Chest Surgery Clinics of North America · doi:10.1016/s1052-3359(25)00555-1 · Cited by 9
Beilstein, M. C., & Silberg, D. G. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00010-8 · Cited by 9
THE MAMMALIAN CELL CYCLE IN NORMAL AND ABNORMAL GROWTH
Orlowski, C. C., & Furlanetto, R. W. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70337-6 · Cited by 13
Noonan, D. M., Severino, A., Morini, M., Tritarelli, A., Manente, L., D’Agnano, I., Starace, G., Baldi, A., Lombardi, D., Albini, A., et al. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20182 · Cited by 11
“In addition, we have observed that the human glioblastoma multiforme T98G cell line, defective in both p16 (Lukas et al., 1995) and p53 (Mercer et al., 1990; Matsumoto et al., 1994), also underwent apoptosis when treated in vitro with the p16-AP9 peptide in a similar extent as A375M cells (M.G.…”
Result
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.